Impact of statin therapy on renal function and long-term prognosis in acute coronary syndrome patients with chronic kidney disease

International Heart Journal

Volumn 51, Issue 5, 2010, Pages 312-318

  Shibui, Toshiyuki ^a   Nakagomi, Akihiro ^a   Kusama, Yoshiki ^a   Atarashi, Hirotsugu ^a   Mizuno, Kyoichi ^b  

^a NIPPON MEDICAL SCHOOL TAMA NAGAYAMA HOSPITAL   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Drug therapy; Myocardial infarction; Renal function; Treatment

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DYSLIPIDEMIA; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART DEATH; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL TIME; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; C-REACTIVE PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIERS ESTIMATE; KIDNEY; KIDNEY FUNCTION TESTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; ROC CURVE;

EID: 78249255494     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.51.312     Document Type: Article

References (19)

1. Imai E, Matsuo S, Makino H, et al. Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res 2008; 31: 1101-1107.
2. Imai E, Horio M, Watanabe T, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009; 13: 621-630.
3. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008; S4-S9. (Review)
4. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97. (Review)
5. Campese VM, Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int 2007; 71: 1215-1222. (Review)
6. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006; 296: 1377-1384. (Review)
7. Tonelli M, Moyé L, Sacks FM, Kiberd B, Curhan G, Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; 138: 98-104.
8. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circula tion 2004; 110: 1557-1563. (Review)
9. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008; 51: 1448-1454.
10. Braunwald E. Unstable angina. A classification. Circulation 1989; 80: 410-414.
11. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
12. Koganei H, Kasanuki H, Ogawa H, Tsurumi Y. Association of glomerular filtration rate with unsuccessful primary percutaneous coronary intervention and subsequent mortality in patients with acute myocardial infarction: from the HIJAMI registry. Circ J 2008; 72: 179-185.
13. Shiba N, Matsuki M, Takahashi J, Tada T, Watanabe J, Shimokawa H. Prognostic importance of chronic kidney disease in Japanese patients with chronic heart failure. Circ J 2008; 72: 173-178.
14. Goicoechea M, de Vinuesa SG, Lahera V, et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: S231-S235.
15. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107: 87-92.
16. Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P. Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif 2008; 26: 291-399. (Review)
17. Vickery S, Webb MC, Price CP, John RI, Abbas NA, Lamb EJ. Prognostic value of cardiac biomarkers for death in a non-dialysis chronic kidney disease population. Nephrol Dial Transplant 2008; 23: 3546-35853.
18. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G, for the Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68: 237-245.
19. Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol 2008; 295: F53-F59.